Cargando…

Promise of metformin for preventing age-related cognitive dysfunction

The expanded lifespan of people, while a positive advance, has also amplified the prevalence of age-related disorders, which include mild cognitive impairment, dementia, and Alzheimer’s disease. Therefore, competent therapies that could improve the healthspan of people have great significance. Some...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhu, Leelavathi N., Kodali, Maheedhar, Shetty, Ashok K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504370/
https://www.ncbi.nlm.nih.gov/pubmed/34380878
http://dx.doi.org/10.4103/1673-5374.320971
_version_ 1784581308317433856
author Madhu, Leelavathi N.
Kodali, Maheedhar
Shetty, Ashok K.
author_facet Madhu, Leelavathi N.
Kodali, Maheedhar
Shetty, Ashok K.
author_sort Madhu, Leelavathi N.
collection PubMed
description The expanded lifespan of people, while a positive advance, has also amplified the prevalence of age-related disorders, which include mild cognitive impairment, dementia, and Alzheimer’s disease. Therefore, competent therapies that could improve the healthspan of people have great significance. Some of the dietary and pharmacological approaches that augment the lifespan could also preserve improved cognitive function in old age. Metformin, a drug widely used for treating diabetes, is one such candidate that could alleviate age-related cognitive dysfunction. However, the possible use of metformin to alleviate age-related cognitive dysfunction has met with conflicting results in human and animal studies. While most clinical studies have suggested the promise of metformin to maintain better cognitive function and reduce the risk for developing dementia and Alzheimer’s disease in aged diabetic people, its efficacy in the nondiabetic population is still unclear. Moreover, a previous animal model study implied that metformin could adversely affect cognitive function in the aged. However, a recent animal study using multiple behavioral tests has reported that metformin treatment in late middle age improved cognitive function in old age. The study also revealed that cognition-enhancing effects of metformin in aged animals were associated with the activation of the energy regulator adenosine monophosphate-activated protein kinase, diminished neuroinflammation, inhibition of the mammalian target of rapamycin signaling, and augmented autophagy in the hippocampus. The proficiency of metformin to facilitate these favorable modifications in the aged hippocampus likely underlies its positive effect on cognitive function. Nonetheless, additional studies probing the outcomes of different doses and durations of metformin treatment at specific windows in the middle and old age across sex in nondiabetic and non-obese prototypes are required to substantiate the promise of metformin to maintain better cognitive function in old age.
format Online
Article
Text
id pubmed-8504370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-85043702021-11-01 Promise of metformin for preventing age-related cognitive dysfunction Madhu, Leelavathi N. Kodali, Maheedhar Shetty, Ashok K. Neural Regen Res Review The expanded lifespan of people, while a positive advance, has also amplified the prevalence of age-related disorders, which include mild cognitive impairment, dementia, and Alzheimer’s disease. Therefore, competent therapies that could improve the healthspan of people have great significance. Some of the dietary and pharmacological approaches that augment the lifespan could also preserve improved cognitive function in old age. Metformin, a drug widely used for treating diabetes, is one such candidate that could alleviate age-related cognitive dysfunction. However, the possible use of metformin to alleviate age-related cognitive dysfunction has met with conflicting results in human and animal studies. While most clinical studies have suggested the promise of metformin to maintain better cognitive function and reduce the risk for developing dementia and Alzheimer’s disease in aged diabetic people, its efficacy in the nondiabetic population is still unclear. Moreover, a previous animal model study implied that metformin could adversely affect cognitive function in the aged. However, a recent animal study using multiple behavioral tests has reported that metformin treatment in late middle age improved cognitive function in old age. The study also revealed that cognition-enhancing effects of metformin in aged animals were associated with the activation of the energy regulator adenosine monophosphate-activated protein kinase, diminished neuroinflammation, inhibition of the mammalian target of rapamycin signaling, and augmented autophagy in the hippocampus. The proficiency of metformin to facilitate these favorable modifications in the aged hippocampus likely underlies its positive effect on cognitive function. Nonetheless, additional studies probing the outcomes of different doses and durations of metformin treatment at specific windows in the middle and old age across sex in nondiabetic and non-obese prototypes are required to substantiate the promise of metformin to maintain better cognitive function in old age. Wolters Kluwer - Medknow 2021-08-04 /pmc/articles/PMC8504370/ /pubmed/34380878 http://dx.doi.org/10.4103/1673-5374.320971 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Madhu, Leelavathi N.
Kodali, Maheedhar
Shetty, Ashok K.
Promise of metformin for preventing age-related cognitive dysfunction
title Promise of metformin for preventing age-related cognitive dysfunction
title_full Promise of metformin for preventing age-related cognitive dysfunction
title_fullStr Promise of metformin for preventing age-related cognitive dysfunction
title_full_unstemmed Promise of metformin for preventing age-related cognitive dysfunction
title_short Promise of metformin for preventing age-related cognitive dysfunction
title_sort promise of metformin for preventing age-related cognitive dysfunction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504370/
https://www.ncbi.nlm.nih.gov/pubmed/34380878
http://dx.doi.org/10.4103/1673-5374.320971
work_keys_str_mv AT madhuleelavathin promiseofmetforminforpreventingagerelatedcognitivedysfunction
AT kodalimaheedhar promiseofmetforminforpreventingagerelatedcognitivedysfunction
AT shettyashokk promiseofmetforminforpreventingagerelatedcognitivedysfunction